ROCKVILLE - MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, announces that it has filed a Form 8-K with the SEC announcing the departure of Dr. Cenk Sumen as Chief Scientific Officer.

Dr. Sumen will maintain a relationship with the Company as a member of MaxCyte's Scientific Advisory Board.

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health.

Contact:

David Deuchler

Tel: +1 415-937-5400

Email: ir@maxcyte.com

Emma Earl

Tel: +44 (0)20 7886 2500

Tel: +44 (0)203 709 5700

Email: maxcyte@consilium-comms.com

(C) 2024 Electronic News Publishing, source ENP Newswire